Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
NEXNF$0.09-0.00(-2.45%)NEXE Innovations Reports Q1 Fiscal 2027 Results and Business Update[8:03:56 PM ET]UREKF$0.120.00(0.00%)Eureka Metals Corp. Announces Rights Offering and Proposed Share Consolidation[7:57:00 PM ET]RMBI$15.860.00(0.00%)RICHMOND MUTUAL BANCORPORATION, INC. ANNOUNCES 2026 THIRD QUARTER FINANCIAL RESULTS Richmond Mutual Bancorporation, Inc., a Maryland corporation (the "Company") (NASDAQ: RMBI), parent company of First Bank Midwest, today reported net ...[7:55:00 PM ET]MVLY$21.69+0.73(+3.48%)Mission Valley Bancorp Reports Third Quarter Results[7:52:00 PM ET]UNIB$21.350.00(0.00%)University Bancorp Closes on the Acquisition of 20% of UIF Corporation for Cash & Stock Worth About $15.2 Million[7:45:00 PM ET]NXTT$5.02+0.17(+3.51%)Next Technology Holding Inc. Announces Board Authorization to Sell or Pledge of Bitcoin Holdings to Reduce Bitcoin Exposure and Enhance Liquidity[7:20:00 PM ET]PRRSF$0.04+0.00(+10.13%)Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement[6:35:00 PM ET]OTAI$10.11+0.00(+0.05%)Spider Digital Technology Ltd. and Starlink AI Acquisition Corporation Announce Definitive Business Combination Agreement[6:30:00 PM ET]REVVF$0.170.00(0.00%)Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario[6:30:00 PM ET]CTSH$64.90+2.38(+3.81%)Cognizant setzt mehr als 25.000 Fachkräfte für die Umsetzung von OpenAI-Lösungen ein, während Unternehmen bahnbrechende KI-Technologien in die Produktion überführen Cognizant (Nasdaq: CTSH) gab heute die Gründung seiner „OpenAI Frontier Capability Group" bekannt, in der mehr als 25.000 Fachkräfte zusammenkommen,...[6:17:00 PM ET]INO$2.06+1.29(+166.91%)INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...[6:01:00 PM ET]KVUE$19.31-0.25(-1.28%)Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on...[5:51:00 PM ET]

HUMA · NASDAQ

Humacyte, Inc.

$0.43 0.00 (-0.95%)

Company overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company uses its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$119M
Employees
218
Headquarters
Durham, NC
Website
humacyte.com
CEO
Laura E. Niklason
Listed
December 1, 2020
P/E
-0.73
Dividend yield
0.00%

Company financials

Revenue
$2M
Gross profit
-$15.1M
Operating income
-$114M
EBITDA
-$112M
Net income
-$97.6M
EPS
-$0.59
Total assets
$111M
Total debt
$65.9M
Gross margin
-748.51%
Net margin
-4,840.82%
Earnings yield
-136.98%

Revenue segmentation

By product

No annual segmentation.

By region

No geographic segmentation.

Price chart

0.290.610.931.251.57
HUMA 1D NASDAQ O0.44H0.44L0.40C0.40-0.07 (-14.09%)Vol1.25M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
HUMAHumacyte, Inc. Stock news Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research
HUMAHumacyte, Inc. Press release Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues GlobeNewswire
HUMAHumacyte, Inc. Press release Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner GlobeNewswire
HUMAHumacyte, Inc. Stock news Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note Zacks Investment Research
HUMAHumacyte, Inc. Press release Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals GlobeNewswire
HUMAHumacyte, Inc. Stock news Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know Zacks Investment Research
HUMAHumacyte, Inc. Press release Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 GlobeNewswire
HUMAHumacyte, Inc. Stock news Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade Zacks Investment Research
HUMAHumacyte, Inc. Stock news Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note Zacks Investment Research
HUMAHumacyte, Inc. Press release Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik GlobeNewsWire
HUMAHumacyte, Inc. Stock news Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why Zacks Investment Research
HUMAHumacyte, Inc. Stock news Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Zacks Investment Research
HUMAHumacyte, Inc. Stock news Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? Zacks Investment Research
HUMAHumacyte, Inc. Press release Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference GlobeNewsWire
HUMAHumacyte, Inc. Press release Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months GlobeNewsWire
HUMAHumacyte, Inc. Legal Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA Business Wire
HUMAHumacyte, Inc. Press release Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions GlobeNewsWire
HUMAHumacyte, Inc. Legal Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA PRNewsWire
HUMAHumacyte, Inc. Press release Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results GlobeNewsWire
HUMAHumacyte, Inc. Press release Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” GlobeNewsWire
See more
FAQ

Questions about Humacyte, Inc.

What does Humacyte, Inc. do?
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company uses its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.
What is HUMA's market cap?
Humacyte, Inc. (HUMA) is a listed stock with a live quote. The latest market cap on this page is $119M.
Where is Humacyte, Inc. headquartered?
Humacyte, Inc. is headquartered in Durham, NC.
How do I get HUMA news from the API?
Call GET /v1/news?tickers=HUMA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does HUMA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for HUMA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the HUMA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs